Temporary FDA Advisory Committee Members, Recommendations, and Agency Actions, 2017-2021

Nikhil Chaudhry; Audrey D Zhang; Jason L Schwartz; Reshma Ramachandran; Joseph S Ross

doi:10.1001/jamanetworkopen.2024.36789

Temporary FDA Advisory Committee Members, Recommendations, and Agency Actions, 2017-2021

JAMA Netw Open. 2024 Oct 1;7(10):e2436789. doi: 10.1001/jamanetworkopen.2024.36789.

Authors

Nikhil Chaudhry¹, Audrey D Zhang², Jason L Schwartz^{1

3}, Reshma Ramachandran^{1

4}, Joseph S Ross^{1

3

4}

Affiliations

¹ Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut.
² Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
³ Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.
⁴ Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.

No abstract available

Plain language summary

This cross-sectional study examines the recommendations and agency actions of temporary and permanent US Food and Drug Administration advisory committee members from 2017 to 2021.

MeSH terms

Advisory Committees*
Committee Membership
Humans
United States
United States Food and Drug Administration*